Department of Cardiology, Campus Benjamin Franklin, CC11, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany.
German Centre for Cardiovascular Research (DZHK), Site Berlin, Germany.
Clin Res Cardiol. 2017 Jul;106(7):551-556. doi: 10.1007/s00392-017-1086-1. Epub 2017 Feb 24.
Hepatitis C virus (HCV) has been associated with cardiomyopathies. Former anti-HCV therapies employing interferon could have serious side effects in patients with advanced heart failure since interferon may adversely impact upon cardiac function. We, therefore, examined whether the novel, interferon-free and highly virus-selective anti-HCV combination therapy might be applicable even in advanced or end-stage heart failure.
In a retrospective series of HCV-positive patients admitted to our institution with suspected cardiac disease, coronary, valvular or hypertensive heart disease was diagnosed in 70/146 (47.9%). Among the others, 36/76 (47.4%) had myocardial disease: LV (32.9%)/RV (13.2%) hypertrophy, RV dysfunction (13.2%)/dilation (6.6%), severe diastolic dysfunction (7.9%), pulmonary hypertension (22.4%). One critically ill patient listed for heart transplantation (HTX) had previously not tolerated an interferon-based protocol. To still improve her chance of enduring transplant survival, we attempted an interferon-free virus-selective antiviral combination drug protocol under careful monitoring of possible side effects. Regarding clinical status she tolerated this treatment well, with the exception of transient severe hyponatremia requiring substitution. Her NYHA functional class improved from II-IV before to class II immediately after successful complete HCV elimination.
Whereas prevalence of cardiac dysfunction and potential benefit from antiviral treatment was reported previously, there is lack of data regarding the response of patients with advanced heart failure. Since the highly HCV-selective drugs used above do not eliminate other cardiotropic viruses and have no direct effect on inflammation, massive improvement in such critically ill patients indicates a causal role of HCV in their cardiac failure, and of HCV elimination in their functional recovery.
丙型肝炎病毒 (HCV) 与心肌病有关。由于干扰素可能对心脏功能产生不利影响,因此以前使用干扰素的抗 HCV 治疗可能会对晚期心力衰竭患者产生严重的副作用。因此,我们研究了新型、无干扰素且高度选择性的抗 HCV 联合治疗方法是否即使在晚期或终末期心力衰竭患者中也适用。
在我们机构收治的疑似患有心脏病的 HCV 阳性患者的回顾性系列研究中,70/146(47.9%)例被诊断为冠状动脉、瓣膜或高血压性心脏病。在其余患者中,36/76(47.4%)例患有心肌疾病:左心室(32.9%)/右心室(13.2%)肥大、右心室功能障碍(13.2%)/扩张(6.6%)、严重舒张功能障碍(7.9%)、肺动脉高压(22.4%)。一位危重症患者被列入心脏移植(HTX)名单,但以前不能耐受基于干扰素的方案。为了提高她耐受移植存活的机会,我们在仔细监测可能的副作用的情况下尝试了一种无干扰素的病毒选择性抗病毒联合药物方案。就临床状况而言,她对这种治疗耐受良好,除了短暂的严重低钠血症需要替代治疗外。她的纽约心脏协会功能分级从治疗前的 II-IV 级改善到治疗后的 II 级。
尽管以前有报道称心脏功能障碍的患病率和抗病毒治疗的潜在益处,但缺乏关于晚期心力衰竭患者的反应的数据。由于上述高度选择性的 HCV 药物不能消除其他心肌病毒,并且对炎症没有直接作用,因此这些重症患者的大量改善表明 HCV 在其心力衰竭中起因果作用,在其功能恢复中消除 HCV。